文献速递免疫规划

既往接种BBIBP-CorV疫苗成人中以NVX-CoV2373疫苗加强接种的安全性与免疫原性

Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine.
PubMed 文献 · Vaccine · 2024-02-15

这项3期观察者盲法随机对照研究在≥18岁既往接种2或3剂BBIBP-CorV的成人中,比较NVX-CoV2373异源加强与BBIBP-CorV同源加强的安全性和免疫原性,约1000名参与者按1:1随机接种单剂。研究达到主要非劣效终点,NVX-CoV2373异源加强的中和应答在统计学上高于BBIBP-CorV同源加强,两种疫苗反应原性均可接受且未发现新安全性问题。

要点

  • NVX-CoV2373异源加强达到主要非劣效终点,中和应答统计学上高于BBIBP-CorV同源加强。
  • 两种疫苗反应原性均可接受,未发现新的安全性问题。
  • 在既往接种BBIBP-CorV者中,NVX-CoV2373异源加强具有高免疫原性和安全性。

核心结论

  • 在既往接种BBIBP-CorV疫苗的成人中,NVX-CoV2373异源加强是高度免疫原且安全的疫苗方案。

研究设计与样本

  • 3期观察者盲法随机对照研究,在≥18岁成人中开展,约1000名参与者按1:1随机接受单剂NVX-CoV2373或BBIBP-CorV加强,此前已接种2或3剂BBIBP-CorV。

主要发现

  • 研究达到主要非劣效终点,NVX-CoV2373异源加强相比BBIBP-CorV同源加强显示出统计学更高的中和应答。
  • 两种疫苗反应原性均可接受,未发现新的安全性问题。
  • 征集性不良事件在接种后7天内收集,非征集性不良事件在加强接种后28天内收集,严重不良事件和特殊关注不良事件在整个研究期间收集。
  • 抗刺突IgG和SARS-CoV-2中和抗体在基线、第14天、第28天和第180天检测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This phase 3 observer-blind, randomized, controlled study was conducted in adults ≥18 years of age to assess the safety and immunogenicity of NVX-CoV2373 as a heterologous booster compared to BBIBP-CorV when utilized as a homologous booster. Approximately 1000 participants were randomly assigned in a 1:1 ratio to receive a single dose of NVX-CoV2373 or BBIBP-CorV after prior vaccination with 2 or 3 doses of BBIBP-CorV. Solicited adverse events (AEs) were collected for 7 days after vaccination. Unsolicited AEs were collected for 28 days following the booster dose and serious adverse and adverse events of special interest (AESI) were collected throughout the study. Anti-spike IgG and neutralizing antibodies against SARS-CoV-2 were measured at baseline, day 14, day 28, and day 180. The study achieved its primary non-inferiority endpoint and also demonstrated statistically higher neutralization responses when NVX-CoV2373 was utilized as a heterologous booster compared with BBIBP-CorV as a homologous booster. Both vaccines had an acceptably low reactogenicity profile, and no new safety concerns were found. Heterologous boosting with NVX-CoV2373 was a highly immunogenic and safe vaccine regimen in those previously vaccinated with BBIBP-CorV.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Toback S, Marchese AM, Warren B, et al. Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine. Vaccine. 2024. PMID: 38365482. doi:10.1016/j.vaccine.2024.02.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。